WilmerHale Advises Volastra Therapeutics in Extended $44M Seed Financing

  • 4.6.2021

On April 6, 2021, Volastra Therapeutics, a biotechnology company developing novel therapies for the prevention and treatment of metastatic cancer, announced the extension of its original $12 million seed round to a total of $44 million. The funding supports the further build-out of Volastra’s technology platform, which exploits unique insights into chromosomal instability to rapidly identify and validate novel targets to block metastasis. In the U.S. alone, more than 350,000 people a year are diagnosed with metastatic cancer. Less than a third respond to targeted or immuno-therapies, making metastasis one of the most pressing unsolved challenges in cancer.

The WilmerHale team advising Volastra was led by Cynthia Mazareas and included Sam Rothberg and Jenna Weissman.

See other News & Publications related to:

See related industries:

Life Sciences